scholarly journals Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A double-blind, randomized, crossover study

Diabetes Care ◽  
2007 ◽  
Vol 30 (10) ◽  
pp. 2447-2452 ◽  
Author(s):  
F. Porcellati ◽  
P. Rossetti ◽  
N. R. Busciantella ◽  
S. Marzotti ◽  
P. Lucidi ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Steady State ◽  
Crossover Study ◽  
Insulin Analogs ◽  
Double Blind ◽  
Acting Insulin ◽  
Long Acting ◽  
Randomized Crossover Study

Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial

2016 ◽  
Vol 124 (05) ◽  
pp. 276-282 ◽  
Author(s):  
V. Cherubini ◽  
B. Pintaudi ◽  
A. Iannilli ◽  
M. Pambianchi ◽  
L. Ferrito ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Analogs ◽  
Open Label ◽  
Acting Insulin ◽  
Long Acting

scholarly journals Effects of insulin detemir versus insulin glargine on food intake and satiety factors in type 1 diabetes

2021 ◽  
Vol 8 (1) ◽  
pp. 31-36
Author(s):  
Mark R Burge ◽  
Imaneh Fallahi ◽  
Madhavi Garimella ◽  
Steve Mitchell
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Glargine ◽  
Insulin Detemir ◽  
Peptide Yy ◽  
Caloric Intake ◽  
Research Unit ◽  
Double Blind ◽  
Acting Insulin ◽  
Long Acting

Background: Insulin detemir is long-acting insulin analog that is weight-neutral compared with other long-acting insulins in patients with type 1 diabetes. One mechanism for this may be an effect of insulin detemir to enhance satiety. We hypothesized that type 1 diabetes patients on insulin detemir will eat fewer calories when presented with a standardized buffet meal following a 24-hour fast as compared to those on insulin glargine. Methods: Ten subjects with C-peptide negative type 1 diabetes participated in a randomized, double-blind crossover study in which they received equivalent doses of either insulin detemir or insulin glargine twice daily for at least 3 weeks. They were subsequently admitted to the UNM Clinical Research Unit for a 24-hour fast, after which they were allowed to eat to satiety from a standardized buffet. Caloric consumption, hunger score and body compositions were measured. Leptin, Ghrelin and Peptide YY were assessed at baseline, after 24-hour fast, and after ingestion of the meal. Results: Subjects were aged 35±11 years, had diabetes for 18±11 years, had A1c levels of 8±1% and BMI of 30±8 kg/m2. Short acting insulin doses were higher for subjects receiving insulin detemir versus insulin glargine (p<0.001). Hunger scores, total energy ingested following the 24-hour fast, and Resting Energy Expenditure did not significant differ between the two study conditions. Conclusion: The weight-neutrality of insulin detemir in type 1 diabetes is not attributable to reduced caloric intake following a fast, or to serum satiety factors.  

Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update

2021 ◽  
pp. 1-9
Author(s):  
Ulrik Pedersen-Bjergaard ◽  
Therese W. Fabricius ◽  
Birger Thorsteinsson
Keyword(s):  
Type 1 Diabetes ◽  
Insulin Analogs ◽  
Acting Insulin ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document